Pyxis Oncology is a preclinical stage biopharmaceutical company that develops therapies to treat cancers. Its product candidates include immune-oncology and antibody drug conjugate therapies for the treatment of various solid tumors, including thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, breast cancer, soft tissue sarcoma, acute myeloid leukemia, and myeloid dysplastic syndrome. The company was founded in 2018 and is based in Cambridge, Massachusetts.